Vera Therapeutics (VERA) Stock Forecast, Price Target & Predictions

VERA Stock Forecast

Vera Therapeutics stock forecast is as follows: an average price target of $26.00 (represents a -43.36% downside from VERA’s last price of $45.90) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

VERA Price Target

The average price target for Vera Therapeutics (VERA) is $26.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $6.00. This represents a potential -43.36% downside from VERA's last price of $45.90.

VERA Analyst Ratings

Buy

According to 5 Wall Street analysts, Vera Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VERA stock is 1 'Strong Buy' (20.00%), 3 'Buy' (60.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Vera Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Mar 21, 2024	Laura Chico	Wedbush	$34.00	$42.87	-20.69%	-25.93%
Jan 26, 2024	Ryan Deschner	Raymond James	$37.00	$30.18	22.60%	-19.39%
Dec 18, 2023	Ryan Deschner	Raymond James	$29.00	$15.84	83.08%	-36.82%
Jan 04, 2023	-	Jefferies	$6.00	$6.37	-5.81%	-86.93%
Jan 04, 2023	-	H.C. Wainwright	$15.00	$18.30	-18.03%	-67.32%
Nov 18, 2022	-	J.P. Morgan	$38.00	$17.62	115.66%	-17.21%
May 02, 2022	-	H.C. Wainwright	$35.00	$20.00	75.00%	-23.75%

Row per page

Go to

The latest Vera Therapeutics stock forecast, released on Mar 21, 2024 by Laura Chico from Wedbush, set a price target of $34.00, which represents a -20.69% decrease from the stock price at the time of the forecast ($42.87), and a -25.93% decrease from VERA last price ($45.90).

Vera Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	3
Avg Price Target	-	-	$33.33
Last Closing Price	$45.90	$45.90	$45.90
Upside/Downside	-100.00%	-100.00%	-27.39%

In the current month, the average price target of Vera Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vera Therapeutics's last price of $45.90. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 28, 2024	Guggenheim	Buy	Buy	Hold
May 10, 2024	Raymond James	Strong Buy	Strong Buy	Hold
Jan 26, 2024	Oppenheimer	-	Outperform	Initialise
Jan 26, 2024	Wedbush	Neutral	Neutral	Hold
Jan 26, 2024	Raymond James	-	Strong Buy	Upgrade
Nov 10, 2023	Jefferies	-	Buy	Upgrade
Jan 04, 2023	Guggenheim	-	Buy	Initialise
Jan 04, 2023	Wedbush	-	Neutral	Downgrade

Row per page

Go to

Vera Therapeutics's last stock rating was published by Guggenheim on Oct 28, 2024. The company gave VERA a "Buy" rating, the same as its previous rate.

Vera Therapeutics Financial Forecast

Vera Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
# Analysts	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

Vera Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. VERA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Vera Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

undefined analysts predict VERA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Vera Therapeutics's previous annual EBITDA (undefined) of $NaN.

Vera Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-
Avg Forecast	$-51.60M	$-46.44M	$-45.46M	$-45.46M	$-43.89M	$-35.00M	$-30.65M
High Forecast	$-51.60M	$-46.44M	$-45.46M	$-36.86M	$-31.58M	$-35.00M	$-30.65M
Low Forecast	$-51.60M	$-46.44M	$-45.46M	$-49.76M	$-48.17M	$-35.00M	$-30.65M
Surprise %	-	-	-	-	-	-	-

Vera Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VERA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Vera Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
SG&A	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

Vera Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to VERA last annual SG&A of $NaN (undefined).

Vera Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-
Avg Forecast	$-0.94	$-0.85	$-0.83	$-0.83	$-0.80	$-0.64	$-0.56
High Forecast	$-0.94	$-0.85	$-0.83	$-0.67	$-0.58	$-0.64	$-0.56
Low Forecast	$-0.94	$-0.85	$-0.83	$-0.91	$-0.88	$-0.64	$-0.56
Surprise %	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Vera Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VERA previous annual EPS of $NaN (undefined).

Vera Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
RAPT	RAPT Therapeutics	$1.07	$30.71	2770.09%	Hold
VTYX	Ventyx Biosciences	$1.78	$33.86	1802.25%	Buy
XLO	Xilio Therapeutics	$1.02	$7.00	586.27%	Buy
ANEB	Anebulo Pharmaceuticals	$1.52	$6.00	294.74%	Buy
ACRV	Acrivon Therapeutics	$6.38	$21.83	242.16%	Buy
ANAB	AnaptysBio	$19.97	$52.00	160.39%	Buy
CGEM	Cullinan Oncology	$13.10	$31.50	140.46%	Buy
MLYS	Mineralys Therapeutics	$12.86	$30.00	133.28%	Buy
ADAG	Adagene	$2.22	$5.00	125.23%	Buy
ALDX	Aldeyra Therapeutics	$4.94	$11.00	122.67%	Buy
COGT	Cogent Biosciences	$9.06	$18.83	107.84%	Buy
TYRA	Tyra Biosciences	$16.21	$31.75	95.87%	Buy
CYTK	Cytokinetics	$51.09	$83.23	62.91%	Buy
CNTB	Connect Biopharma	$0.98	$1.50	53.06%	Buy
EWTX	Edgewise Therapeutics	$31.51	$45.00	42.81%	Buy
TARS	Tarsus Pharmaceuticals	$46.89	$62.00	32.22%	Buy
THRD	Third Harmonic Bio	$12.46	$16.15	29.61%	Buy
DICE	DICE Therapeutics	$47.55	$60.00	26.18%	Buy
TVTX	Travere Therapeutics	$17.39	$21.75	25.07%	Buy
ETON	Eton Pharmaceuticals	$10.50	$13.00	23.81%	Buy
VERA	Vera Therapeutics	$45.90	$26.00	-43.36%	Buy

VERA Forecast FAQ

Is Vera Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, Vera Therapeutics (VERA) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 3 'Buy' recommendations, accounting for 80.00% of VERA's total ratings.

What is VERA's price target?

Vera Therapeutics (VERA) average price target is $26 with a range of $6 to $38, implying a -43.36% from its last price of $45.9. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Vera Therapeutics stock go up soon?

According to Wall Street analysts' prediction for VERA stock, the company can go down by -43.36% (from the last price of $45.9 to the average price target of $26), down by -17.21% based on the highest stock price target, and down by -86.93% based on the lowest stock price target.

Can Vera Therapeutics stock reach $70?

VERA's average twelve months analyst stock price target of $26 does not support the claim that Vera Therapeutics can reach $70 in the near future.

What are Vera Therapeutics's analysts' financial forecasts?

Vera Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-110M (high $-97.226M, low $-114M), average SG&A $0 (high $0, low $0), and average EPS is $-1.997 (high $-1.773, low $-2.075). VERA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-189M (high $-180M, low $-193M), average SG&A $0 (high $0, low $0), and average EPS is $-3.442 (high $-3.285, low $-3.52).